

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001969082
Filer CCC XXXXXXXXX
Is this a LIVE or TEST Filing? LIVE TEST

Submission Contact Information

Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer Revolution Medicines, Inc.
SEC File Number 001-39219

Address of Issuer

700 SAGINAW DR
REDWOOD CITY
CALIFORNIA
94063

Phone 650-481-6801
Name of Person for Whose Account the Securities are To Be Sold Cislini Jeff

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	ETRADE Financial Corporation 3 Edison Drive Alpharetta GA 30005	1432	64339.76	168219391	12/16/2024	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from	Is this	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
--------------------	-------------------	-----------------------------------	---------------------	---------	---------------------	-------------------------------	-----------------	---------------------

			Whom Acquired	a Gift?		
Common Stock	03/04/2021	Restricted stock unit grant	Issuer	<input type="checkbox"/>	86	03/04/2021 Services rendered
Common Stock	03/01/2022	Restricted stock unit grant	Issuer	<input type="checkbox"/>	190	03/01/2022 Services rendered
Common Stock	09/01/2022	Restricted stock unit grant	Issuer	<input type="checkbox"/>	192	09/01/2022 Services rendered
Common Stock	03/01/2023	Restricted stock unit grant	Issuer	<input type="checkbox"/>	495	03/01/2023 Services rendered
Common Stock	03/01/2024	Restricted stock unit grant	Issuer	<input type="checkbox"/>	469	03/01/2024 Services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jeff Cislini c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	09/16/2024	1454	64245.43
Jeff Cislini c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	10/11/2024	6000	301026.60
Jeff Cislini c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	11/06/2024	6000	360000.00
Jeff Cislini c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	11/15/2024	2554	140811.47

144: Remarks and Signature

Remarks The transaction dated October 11, 2024, involving 6,000 shares, was executed in multiple trades in prices ranging from \$50.00 to \$50.45. The gross proceeds reported in the Gross Proceeds Column above reflects the use of the weighted average sale price of \$50.1711. The transaction dated November 15, 2024, involving 2,554 shares, was executed in multiple trades in prices ranging from \$54.91 to \$55.51. The gross proceeds reported in the Gross Proceeds Column above reflects the use of the weighted average sale price of \$55.1337.

Date of Notice 12/16/2024

Date of Plan
Adoption or
Giving of
Instruction, If
Relying on
Rule 10b5-1

05/31/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature Jack Anders, as Attorney-in-Fact for Jeff Cislini

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)